<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03152578</url>
  </required_header>
  <id_info>
    <org_study_id>PANAG-001</org_study_id>
    <nct_id>NCT03152578</nct_id>
  </id_info>
  <brief_title>Topical Use of 20% Beta Caryophyllene Alone And In Combination With 0.025% Capsaicin for Pain Caused by Osteoarthritis Of The Knee</brief_title>
  <official_title>Randomized, Double Blind, Placebo Controlled Crossover Trial With Open Label Extension Of Topical 20% Beta Caryophyllene Alone And In Combination With 0.025% Capsaicin In The Treatment Of Pain Caused By Osteoarthritis Of The Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Panag Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Panag Pharma Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study consists of a randomized, double-blind, placebo-controlled crossover trial with&#xD;
      open label extension evaluating a topical natural health cream containing ÃŸ-caryophyllene&#xD;
      alone and in combination with 0.025% capsicum oleoresin against placebo. At the end of the&#xD;
      randomized controlled phase of the trial all participants will be given open-label&#xD;
      combination cream to be administered over the subsequent 3 weeks.&#xD;
&#xD;
      Primary Endpoint: Evaluation of improvement in pain interference as measured by the BPI in&#xD;
      individuals who are experiencing pain due to osteoarthritis of the knee.&#xD;
&#xD;
      Secondary Endpoints: Secondary endpoints are: Confirmation of safety of the topical cream&#xD;
      when used daily over 10 weeks.&#xD;
&#xD;
      Further evaluation will include overall patient satisfaction with the products tested.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score Diary</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change in mean daily pain diary score from baseline (average pain score over 7 days pre-treatment) to post treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BPI-Short Form</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Impression of Change</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>BetaC + Capsacian</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1-3 mls BetaC + Capsacian applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BetaC Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1-3 mls BetaC applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1-3 mls Placebo applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>BetaC + Capsaicin Topical Cream</intervention_name>
    <description>BetaC + Capsacin Topical Cream applied to painful knee area 3 times per day.</description>
    <arm_group_label>BetaC + Capsacian</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>BetaC Topical Cream</intervention_name>
    <description>BetaC Topical Cream Cream applied to painful knee area 3 times per day.</description>
    <arm_group_label>BetaC Only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Topical Cream</intervention_name>
    <description>Placebo Cream applied to painful knee area 3 times per day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Osteoarthritis of the knee according to American College of Rheumatology criteria:&#xD;
             Knee pain with 3 of the following:&#xD;
&#xD;
               -  age &gt;50 years&#xD;
&#xD;
               -  stiffness less than 30 min&#xD;
&#xD;
               -  crepitus,&#xD;
&#xD;
               -  bony tenderness,&#xD;
&#xD;
               -  bony enlargement,&#xD;
&#xD;
               -  no palpable warmth&#xD;
&#xD;
          -  Moderate to severe pain, as defined by an average 7-day pain score of greater than 4.0&#xD;
             on an 11-point numerical rating scale for pain intensity (NRS-PI).&#xD;
&#xD;
          -  All concurrent medications taken for any reason stable for 14 days&#xD;
&#xD;
          -  Ability to follow protocol with reference to cognitive and situational factors (e.g.&#xD;
             stable housing, ability to attend visits)&#xD;
&#xD;
          -  Ability to read and write English&#xD;
&#xD;
          -  Willing and able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently using other topical agents for treatment of pain or inflammation&#xD;
&#xD;
          -  Use of glucosamine, methysulfonylmethane or other regular anti-inflammatories within 2&#xD;
             weeks prior to completing baseline pain measure and during the trial&#xD;
&#xD;
          -  Presence of significant medical disorder that would compromise the participant's&#xD;
             safety to take part in the trial (e.g. cancer, immunosuppressed)&#xD;
&#xD;
          -  Pregnant and breastfeeding women.&#xD;
&#xD;
          -  Type I or Type II diabetes and other endocrine disorders&#xD;
&#xD;
          -  Use of exercise or transcutaneous electrical nerve stimulation prior to and during the&#xD;
             trial&#xD;
&#xD;
          -  A history or present disease (i.e. inflammatory, infectious joint disease) which may&#xD;
             affect the outcome of the trial&#xD;
&#xD;
          -  Currently taking NHPs for joint health&#xD;
&#xD;
          -  Currently enrolled in other clinical trial involving a pharmaceutical treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

